Thursday, October 30, 2014

Ariana Pharma Joins Win Consortium

PARIS, FRANCE & CAMBRIDGE, MASS. -- Ariana Pharma, developer of innovative clinical data analysis and diagnostic solutions for the healthcare sector, today announced it has joined the WIN Consortium as an official technology partner. The Consortium (Worldwide Innovative Networking in personalized cancer medicine) is a global collaboration of 40 leading organizations whose aim is to develop more effective cancer diagnostics and therapeutics, shorten clinical trial timelines and reduce the overall cost of cancer care.

TxCell Achieves Positive Results for Col-Treg in Model of Autoimmune Uveitis

VALBONNE, FRANCE -- TxCell SA (FR0010127662 – TXCL), a biotechnology company developing innovative, economically viable, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that TxCell researchers have achieved positive results for Col-Treg, its second product candidate from its ASTrIA platform, in a model of autoimmune uveitis, a leading cause of blindness with very limited treatment options.

First Thin Smart Fabric Sensors to Measure All Aspects of Physicality

BERKELEY, CALIF. -- BeBop Sensors, Inc. www.bebopsensors.com, the wearable sensor technology company created by musical instrument inventor Keith McMillen and KMI, announced today their first product, the BeBop Wearable Smart Fabric Sensor, the first and only ultra thin wearable smart fabric sensor that measures all aspects of physicality, including bend, location, motion, rotation, angle, and torque.  Employing BeBop’s patented proprietary Monolithic Fabric Sensor Technology, BeBop fabric sensors continuously provide real-time reporting on force, x/y location, bend, twist, size, stretch and motion for markets, including clothing and protective wear, shoes, healthcare devices, athletic equipment, automotive, robotics, aerospace, gaming, biometrics, prosthetics, recycling monitors and appliance markets.

Compugen Discloses Successful Validation Results for Novel B7/CD28–like Cancer Immunotherapy Target Candidate

TEL AVIV, ISRAEL -- Compugen Ltd. (NASDAQ: CGEN) today disclosed successful experimental data for CGEN-15027, a Compugen-discovered immune checkpoint target candidate. The experimental results include its expression in the cancer microenvironment, both on cancer cells derived from lung, breast, and liver cancer patients, and on tumor infiltrating immune cells. In addition, the disclosed data demonstrate CGEN-15027’s inhibitory effect on cancer-specific immune cells. These results suggest that CGEN-15027 has strong potential to serve as a target for monoclonal antibody (mAb) cancer therapy with a mechanism of action that is potentially distinct from previously-disclosed Compugen checkpoint target candidates.

Keysight Technologies to Demonstrate Hardware and Electronic Design Automation Software Solutions at EPEPS 2014

SANTA ROSA, CALIF. -- Keysight Technologies, Inc. today announced it will demonstrate its latest hardware and electronic design automation software solution releases at EPEPS 2014, Embassy Suites Portland, Portland, Oregon, Oct. 26-29. Keysight is a silver-level sponsor of the event. During EPEPS 2014, Keysight technical experts and application engineers will host informal discussions and demonstrations of the company’s electromagnetic simulation and measurement tools. These tools help designers efficiently combine IC, package and board layouts for simulation, analysis and measurement of multigigabit channels. This includes single-ended DDR, high density differential PCIe®, extreme data rates of 100 GB Ethernet and more.

Tuesday, October 28, 2014

Integrated Biometrics Sharing Biometric Fingerprinting Expertise at Industry Events

SPARTANBURG, S.C. -- Integrated Biometrics, developers of the world’s smallest and lightest FBI compliant fingerprint scanners, is sharing its technological expertise and leadership at two major industry events this month. Business Development Executive Thomas Buss is presenting at the Biometrics 2014 conference in London, England, and the company will also be participating in the 121st Annual IACP Conference and Exposition in Orlando, Florida.

Tuesday, October 21, 2014

Precision Marketing Partners Helping Lifestyle Medical Center Spread the Word About Preventative Health and Well-Being Programs

RALEIGH & DURHAM, N.C. -- Precision Marketing Partners, a full-service marketing firm for the medical and healthcare industry, is pleased to announce it has been selected by Lifestyle Medical Center to provide inbound marketing, branding, creative design and strategic planning services for the Durham-based group and its health and well-being programs. Precision Marketing Partners will be redeveloping the LifestyleMedicalCenters.com website as part of a full marketing plan the firm is building, including social media, multimedia, and other proven-effective marketing tools to help attract new patients.